AkzoNobel Puts Merger Remedies at ~EUR500M Revenue; 2026 Deal Costs ~EUR100M
AXTA sits 41% above its 52-week low of $24.937.
Summary
AkzoNobel's Q&A transcript sizes the merger remedies at just under EUR500 million of combined revenue and flags roughly EUR100 million of 2026 merger cash costs, while keeping the $600 million synergy target intact.
Key Events · M&A and Partnerships · AXTA
-
Remedy Package Sized at ~EUR500M Revenue
Together, AkzoNobel's European Refinish business and Axalta's US Wood Coatings business generate a bit less than EUR500 million of revenue, with profitability roughly at the 19%-20% target level for the combined company.
-
$600M Synergy Target Held Despite Remedies
The $600 million cost-synergy commitment was calculated across possible remedy scenarios and remains protected, management says; procurement and SG&A synergies, about two-thirds of the total, are to be front-loaded in years one and two.
-
2026 Merger Cash Costs ~EUR100M
Merger-related cash out for full year 2026 will be roughly EUR100 million, maybe just above, with the spend weighted to the second half as integration preparation ramps.
-
Divestiture Processes Underway
Axalta is running a structured process for the US wood business, while AkzoNobel has begun reaching out to potential buyers for Refinish Europe; no pricing or buyer has been disclosed.
Analysis · AXTA · Industrial Applications And Services
Hard numbers now frame the two divestitures needed to clear the AkzoNobel-Axalta merger. AkzoNobel's European Refinish business and Axalta's US Wood Coatings business together generate a bit less than EUR500 million of revenue, at roughly the 19%-20% margin target for the combined group. Management says the $600 million cost-synergy commitment is protected regardless of the remedies, and that merger-related cash out for 2026 will be roughly EUR100 million, weighted to the second half. Timing mechanics matter here: the US remedy must close before the merger can close, while Europe only needs a signed agreement with an acceptable buyer, so the later-starting European process is not necessarily on the critical path. Shareholder votes already passed on August 5 and EU clearance is expected with conditions, leaving execution of these two sales and the price realized on them as the remaining risk.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29% of the 1517 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXTA was trading at $35.14 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $24.94 to $38.61. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.